Related Experiment Video
Updated: Sep 17, 2025
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Bis-type Triaziquone Induces Apoptotic Effects in Human OEC-M1 Oral Cancer Cells
Chung-Chi Hsu1, Bu-Miin Huang2,3, Yeng-Ting Wu4,5
1School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C.
Background/Aim:
Oral cancer is a major global public health concern. Despite advancements in treatment, the 5-year survival rate for patients with oral cancer remains low. Developing new therapies or drugs is essential for improving patient outcomes. This study aimed to evaluate the anticancer effects of bis-type triaziquone (BTZQ), a synthesized chemical compound, in an oral cancer cell line.
Materials And Methods:
The oral cancer cell line OEC-M1 and oral fibroblast (OF) cells were used in this study. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, propidium iodide staining, and immunoblotting assays were performed to assess cell viability, DNA fragmentation, and protein expression, respectively.
Results:
MTT assays showed that BTZQ significantly reduced OEC-M1 cell viability, with OEC-M1 cells being more sensitive to BTZQ than OF cells. Additionally, BTZQ increased the percentage of OEC-M1 cells in the subG1 phase and induced PARP cleavage, both indicators of apoptosis. Furthermore, BTZQ activated the expression of initiator caspases (caspase-8 and caspase-9) and effector caspases (caspase-3 and caspase-7) in OEC-M1 cells. Furthermore, treatment with BTZQ significantly induced DNA damage, NF-κB activation, and Fas expression.
Conclusion:
BTZQ effectively reduces the viability of OEC-M1 cells, showing greater toxicity to them compared to normal OF cells. It also induces several apoptotic features, including an increased subG1 phase population, PARP cleavage, and caspase activation in OEC-M1 cells, highlighting its potential as an oral cancer therapeutic by promoting apoptosis.
Insights
Bis-type triaziquone (BTZQ) effectively reduced oral cancer cell viability and induced apoptosis, showing greater toxicity to cancer cells than normal cells. This compound shows potential as a novel oral cancer therapeutic agent.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Oral cancer presents a significant global health challenge with low survival rates despite current treatments.
- Novel therapeutic strategies are crucial for improving patient outcomes in oral cancer care.
Purpose of the Study:
- To investigate the anticancer effects of the synthesized compound bis-type triaziquone (BTZQ) on an oral cancer cell line.
- To evaluate the selective toxicity of BTZQ towards oral cancer cells compared to normal oral fibroblasts.
Main Methods:
- Utilized the OEC-M1 oral cancer cell line and oral fibroblast (OF) cells.
- Assessed cell viability using MTT assays.
- Analyzed apoptosis through propidium iodide staining and immunoblotting for DNA fragmentation and protein expression (PARP cleavage, caspase activation).
Main Results:
- BTZQ significantly decreased OEC-M1 cell viability, demonstrating higher sensitivity in cancer cells than normal fibroblasts.
- BTZQ induced apoptosis in OEC-M1 cells, evidenced by an increased subG1 phase population and poly (ADP-ribose) polymerase (PARP) cleavage.
- The compound activated key apoptotic pathways, including initiator (caspase-8, -9) and effector (caspase-3, -7) caspases, induced DNA damage, NF-κB activation, and Fas expression.
Conclusions:
- BTZQ exhibits potent cytotoxic effects against oral cancer cells (OEC-M1) while sparing normal oral fibroblasts (OF).
- The mechanism of action involves the induction of apoptosis through caspase activation and DNA damage.
- BTZQ demonstrates significant potential as a therapeutic agent for oral cancer, warranting further investigation.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...